French Court Denies Roche Action Over Avastin In AMD
This article was originally published in SRA
Executive Summary
A judge at France's top administrative court, the Conseil d'Etat, has denied a request from Roche to suspend the government's decision to reimburse its anticancer, Avastin (bevacizumab), for the off-label indication of wet age-related macular degeneration (AMD)1.
You may also be interested in...
Roche, Novartis Lose French Court Battle Over Off-Label Use Of Avastin In AMD
Roche and Novartis have been unsuccessful in their attempt to stop the French authorities using Avastin off label in wet AMD for financial reasons.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.